



Appendix – 3B

CS Undertaking regarding Valuation

September 27, 2023

To,  
The General Manager,  
Department of Corporate Services,  
BSE Limited,  
P.J. Towers, Dalal Street,  
Mumbai - 400 001.

BSE Scrip Code – 532531

Dear Madam/ Sir,

Re.: Scheme of Arrangement amongst Strides Pharma Science Limited (“Strides” or “Transferor Company 1” or “Demerged Company 1”) and Steriscience Specialties Private Limited (“Steriscience” or “Transferor Company 2” or “Demerged Company 2”) and Stelis Biopharma Limited (“Stelis” or “Transferee Company” or “Resulting Company”) and their respective shareholders (“Draft Scheme”), presented under Section 230-232 read with other applicable provisions of the Companies Act, 2013.

With reference to the above, we certify/ confirm that: -

- (i) No material event impacting the valuation has occurred during the intervening period of filing the scheme documents with the Stock Exchange and the period under consideration for valuation; and
- (ii) There are no past defaults of listed debt obligations of the entities forming part of the scheme.

Thanks & Regards,  
For Strides Pharma Science Limited,

Manjula Ramamurthy  
Company Secretary  
ICSI Membership No.: A30515



Strides Pharma Science Limited

CIN: L24230MH1990PLC057062

Corp. Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru - 560076, India, Tel : +91 80 6784 0000

Regd. Off: 201, Devavrata, Sector 17, Vashi, Navi Mumbai - 400 703, India, Tel : +91 22 2789 2924 / 3199

corpcomm@strides.com | www.strides.com